
Jushi

Investor Presentation

MAY 2020



C S E : J U S H O T C Q X : J U S H F



Disclaimers

The information contained in this presentation has been prepared by Jushi Holdings Inc. ("Jushi" or the "Company") and contains information pertaining to the business, operations and assets of Jushi and its subsidiaries. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company, and (c) is not to be considered as a recommendation by Jushi that any person make an investment in the Company. The Company is not liable for the accuracy and completeness of the information provided in this presentation. Liability claims against the Company relating to damage of any kind caused by the use or non-use of the information provided or by the use of incorrect or incomplete information are excluded, unless there is evidence of willful intent or gross negligence on the part of the Company.

FORWARD LOOKING STATEMENTS

This presentation contains certain "forward-looking information" within the meaning of applicable securities laws, including Canadian securities laws and U.S. securities laws. All information, other than statements of historical facts, included in this document that address activities, events or developments that Jushi expect or anticipate will or may occur in the future constitutes forward-looking information. Forward-looking information is often, but not always, identified by the words, "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes, among others, information regarding: future business strategy; competitive strengths, goals, expansion and growth of Jushi's business; operations and plans, including new revenue streams; the completion of contemplated acquisitions by Jushi of additional assets; roll out of new operations; the implementation by Jushi of certain product lines; implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the expansion into additional U.S. and international markets; any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations for other economic, business, regulatory and/or competitive factors related to Jushi or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information and statements are not based on historical facts but instead are based on assumptions and estimates of management of Jushi at the time they were provided or made, based on factors that management believes are appropriate and reasonable in the circumstances, and involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Jushi, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information and statements. Such factors, risks and uncertainties which are more fully described in the Company's Management Discussion & Analysis dated May 7, 2020 and other filings with securities and regulatory authorities which are available at www.sedar.com. Although Jushi has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information and statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such information and statements. Forward-looking information and statements are provided and made as of the date hereof and Jushi does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law. In addition, this presentation may contain forward-looking statements attributed to third party industry sources. Accordingly, any such statements are qualified in their entirety by reference to, and are accompanied by, the information and factors discussed throughout this presentation.

The Company anticipates that subsequent events and developments may cause their views to change and the Company specifically disclaims any obligation to update these forward-looking statements, except as required by applicable law. This presentation does not contain all information that a prospective investor may require. It is an overview only and does not contain all the information necessary for investment decisions.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent any forward-looking statement in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to risks as set out above under the heading "Forward Looking Statements". The Company's actual financial position and results of operations may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual financial position or results of operations.

Disclaimers Continued

NO OFFERS

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

The securities of the Company described herein have not been and will not be registered under the United States federal or state securities laws and may not be offered or sold in the United States, or to, or for the account or benefit of, "U.S. Persons" as such term is defined in Regulation S under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), unless an exemption from registration is available. Prospective investors will be required to represent, among other things, that they meet the requirements of an available exemption from the registration requirements of the U.S. Securities Act and are familiar with and understand the terms of the offering and have all requisite authority to make such investment.

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL SECURITIES REGULATOR PASSED ON THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

THIRD PARTY INFORMATION

This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

TARGET AUDIENCE

This presentation is only addressed to those persons, which have been explicitly determined by the Company as recipients. The Company did not and will not authorize any third parties to distribute this presentation or make it available to persons not determined by the Company or to the public. Any unauthorized distribution or disclosure will constitute an infringement of the concluded non-disclosure agreement and the Company reserves the right to take further legal action in such cases. No action has been (or will be) taken by the Company that would permit the possession or distribution of this presentation. Persons into whose possession this presentation may come are required to inform themselves of and observe any corresponding restrictions. The Company does not accept any responsibility for any violation by any person of any such restrictions.

REGULATORY

Potential investors are aware that the cannabis market is highly regulated, and that various permits and authorizations are necessary for the import, distribution, sale or other business activities related to medicinal cannabis. The respective regulations can be subject to change, which might affect the permits required. This presentation does not intend to advertise the products of the Company. Any reference to the products serves only the information of potential investors and shall not incite the purchase of the products.

<u>COPYRIGHT</u>

All brands and trademarks mentioned in this presentation and possibly protected by third parties are subject without restriction to the provisions of the applicable trademark law and the ownership rights of the respective registered owners. The mere fact that a trademark is mentioned should not lead to the conclusion that it is not protected by the rights of third parties. The copyright for published objects created by the Company remains solely with the Company. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without the Company's agreement.

CURRENCY

All references to \$ or "dollar" in this presentation are references to USD, unless otherwise indicated.

.Ushi

A Bold, Principled Leader in Cannabis & Hemp

Senior Management Team & Board of Directors

Experienced Talent Leading Buildout and Execution



Jim Cacioppo

Founder, Chairman and CEO

Jim brings managerial, start-up, financial and investing experience to his role as Founder, Chairman and CEO of Jushi. Prior to founding Jushi, Jim spent over two decades managing the business and allocating capital in senior management positions at several large hedge funds. Jim is Co-Founder and Managing Partner of One East Partners (\$2.3 billion (peak AUM)). Jim earned his BA from Colgate University and his MBA from Harvard University.



Jon Barack

Founder, Co-President, Corporate Secretary

Jon brings extensive financial and cannabis industry investing experience to his role as Founder, Co-President and Corporate Secretary at Jushi. Jon spent over 10 years in investments at various hedge funds, including five years of cannabis investing. Jon earned his BA from Princeton University and his JD/MBA from Northwestern University.



Erich Mauff

Founder, Co-President, Director

Erich brings financial and managerial experience to his role as Founder, Co-President and Director of Jushi. Erich spent over 20 years at Deutsche Bank, first heading Capital Markets & Treasury Solutions group, then serving as Managing Director and Vice Chairman of Corporate Finance North America. Erich's fierce work ethic extends beyond his executive experience—in 1992, Erich competed in the Olympics for South Africa's Men's rowing team. Erich earned his BA from Brown University.



Kim Bambach

EVP, Chief Financial Officer

Kim brings impressive financial and executive experience to her position as CFO at Jushi. Prior to joining the Jushi team, Kim served as CFO for a number of high growth ventured back startups including Bidtellect and HookLogic. Kim earned her BA from SUNY Brockport and her MBA from Pace University.

Senior Management Team & Board of Directors

Experienced Talent Leading Buildout and Execution



Max Cohen

Director

Mr. Cohen is the Founder and CEO of The Clinic[™], a large-scale cannabis retailer. Max is a founding member of the Marijuana Industry Group and a member of the Board of Directors for the National Cannabis Industry Organization. Max was a founding board member pre-IPO of Green Thumb Industries (GTI). Max earned his BS in Business Administration from the University of Montana.



Stephen Monroe

Director

Mr. Monroe has a robust record of accomplishment as President of a financial services company and vast expertise in financial markets and risk management. Steve is President and Managing Partner of Liquid Capital Alternative Funding (LCAF), an asset-based lender. Prior to joining LCAF, Steve served as National Sales Manager for Short Duration Products at JP Morgan; and previously in a variety of senior management positions covering cash and short duration products at Barclays and the Royal Bank of Scotland. Steve earned his BA from Williams College.



Peter Adderton

Director

Mr. Adderton has over 30 years of invaluable operational and marketing expertise that he brings to his role as Director at Jushi. Peter is a Director and Founder of Boost Mobile, a wireless telecommunications brand based in Australia. Under his leadership, Boost Mobile USA was purchased by Nextel/Sprint and remains a wholly owned subsidiary of Sprint Nextel. Peter graduated from Sydney Technical College.



Ben Cross

Director

Mr. Cross is a seasoned leader who has been at the helm of several companies. Benjamin brings more than 20 years of extensive financial markets experience and commodities knowledge to his role as Director at Jushi. Benjamin spent 20 years at Morgan Stanley in the Commodities Division until his retirement in 2015 as a Managing Director at the firm. Benjamin earned his BS from Cornell University.

Transaction Highlights Since RTO⁽¹⁾

State	Asset	Status at RTO ⁽¹⁾	Current Status ⁽²⁾⁽³⁾
Pennsylvania	Deal 1) Up to 12 retail locations Deal 2) Up to 3 retail locations	LOI	Deal 1) Closed Deal 2) Definitive Agreement
Illinois	2 retail locations (Sauget and Normal) with rights to open an additional 2 retail locations	LOI	Closed
California	Santa Barbara retail location; Culver City retail license	Definitive Agreement, Applied	Definitive Agreement/Selected as 1 of 3 to move forward in the approval process
Virginia	Vertically integrated license with rights to add up to five more retail locations	LOI	Closed
Nevada	Cultivation, production and distribution license	Definitive Agreement	MSA Closed ⁽⁴⁾
Ohio	Processing license	LOI	MSA Closed ⁽⁴⁾

(1) Jushi listed publicly via RTO on June 10, 2019

(2) There is no assurance proposed transactions labeled "LOI," "Definitive agreement" or "Applied" will be completed on terms acceptable by the Company

(3) As of May 11, 2020

(4) Management Services Agreement; equity transfer to follow

Key Achievements

Jushi leveraging Unique Platform to Drive Long-Term Shareholder Value

- Experienced management team with a successful track record of monetizing assets, investing in the cannabis industry, deal structuring, raising capital, allocating capital and identifying distressed assets
 - Sold minority interest in New York state medical marijuana license for a total estimated value of approximately \$15 to \$20 million, 3-4x the initial investment
 - Raised approximately \$185 million⁽¹⁾ over the last two years; Management and insiders invested approximately \$40 million
 - Focused on leveraging operating structure to create EBITDA accretive M&A deals
- Acquired enviable footprint focused on high quality, fast growing, limited license markets
 - Acquired four permitted entities in Pennsylvania, allowing for 12 medical marijuana dispensaries, and is under a definitive agreement to acquire one additional permitted entity in PA, allowing for an additional three locations. Currently operates six locations under the BEYOND / HELLO brand in PA
 - Acquired two Illinois dispensaries, with the option of adding two additional dispensaries
 - Acquired the majority membership interests of one of only five vertically integrated licenses in Virginia. The Company anticipates adding up to five additional cannabis dispensing facilities, for a total of six in the state
 - Anticipates owning and operating a store in Santa Barbara, CA in the second half of 2020, subject to the closing of a related acquisition agreement
- Solid balance sheet and disciplined approach to capital deployment targeting cash generating or soon to be cash generating assets
 - Pro forma for financing, cash and marketable securities were approximately \$70 million as of December 31, 2019
 - Avoided deploying capital in "crowded" markets with limited growth potential

Financial Highlights and Outlook

Fourth Quarter 2019

- Revenue of \$6.0 million, an increase of 68% as compared to the third quarter of 2019
- Gross profit of \$2.7 million, an increase of 73% as compared to the third quarter of 2019
- Pro forma for financing, cash and marketable securities were approximately \$70 million as of December 31, 2019

First Quarter 2020

- Revenue of \$8.6 million, a sequential increase of 43% as compared to the fourth quarter of 2019
- Annualized revenue run-rate for March 2020 of approximately \$50 million

Outlook

• Jushi remains in position to achieve \$200 to \$250 million in revenue in 2021, through continued investment in and the development of the markets in which it operates, including the closing of acquisitions




Our Key Attributes

Capabilities to Drive Long-term Value Through Vertical Integration



Our Core Advantage

Jushi Maintains a Disciplined Four Pillar Capital Allocation Methodology:



ULTRA-LIGHT CAPITAL INTENSITY

Applying for new licenses

Target States: IL, CA, FL, GA, NJ, NY

LIGHT CAPITAL INTENSITY

Opportunistically purchasing existing retail dispensaries or manufacturing facilities

Target States: IL, PA, CA, NV, OH

MEDIUM CAPITAL INTENSITY

Purchasing or building both retail distribution and manufacturing facilities in a specific state

Target States: PA, IL, NV

HEAVY CAPITAL INTENSITY

Purchasing fully integrated licenses (cultivation, manufacturing, retail) in limited license medical markets


Target State: VA

Footprint



Strategic Market Selection

Targeting attractive adult-use and limited license medical markets





Operational Highlights

STRATEGIC EXPANSION IN LIMITED LICENSE MARKETS

Established a presence across multiple limited license markets and jurisdictions

Pennsylvania

 Acquired four entities, with another under definitive agreement, allowing for a total of up to 15 retail stores, representing 10% of the stores allowed in the Commonwealth

Illinois

 Acquired business with two licensed dispensaries located in Sauget and Normal. Both locations have begun adult-use sales.
Each dispensary is eligible to seek approval to open a second retail location

Virginia

- Acquired one of five conditionally approved licensees in an attractive early stage market
- Senate Bill 976 allows for five additional dispensaries and removed the 5% THC cap. Additionally, patients may now receive up to 10mg per dose

Santa Barbara, California

 Definitive agreement executed to acquire an adult-use store in Santa Barbara, a limited license jurisdiction with 1 of 3 dispensary licenses Building production capacity in Virginia, Nevada, Ohio and New York

Virginia

 Acquired a pharmaceutical processor for medical cannabis extracts with conditional approval for a vertically-integrated license in the Commonwealth's most densely populated and highest-income designated health service area

Nevada

 Under definitive purchase agreement, Jushi's subsidiary ("Production Excellence") to acquire target operator with medical and adult-use cannabis cultivation, processing, distribution and hemp handler licenses

Ohio

• Operational and consulting relationship with a provisionally licensed medical marijuana processor

New York

• Owner of Industrial Hemp CBD Processor License

MANAGEMENT CONSISTS OF INDUSTRY EXPERTS

Management maintains a disciplined and risk adjusted approach to capital allocation

- Enter markets with long-term competitive advantage
- Operations with clear path to strong cash flow
- Purchase for combination of cash, notes and equity
- Management and insiders have invested ~\$40 million of their own money into the business
- Operate in highly desirable states (e.g. PA, IL, VA)


Operations Team

- Acquired award winning operating team from the Clinic[™] with over 10 years of experience
- Significant operating experience in cultivation, extraction and retail processes

Medical

• Partnered with Dr. Laszlo Mechtler, a world-renowned expert and a foremost leading U.S. physician in the study of therapeutic benefits of cannabinoids and related research

Market Profile



- Pennsylvania Market Overview⁽¹⁾⁽²⁾⁽³⁾
- Pennsylvania is the fifth-largest state in the country, home to nearly 13 million people and operates as a high barrier market with limited market participation
- As of February 2020, approximately 290,000 patients and caregivers in the state had registered to participate in the medical cannabis program
- Demand is beyond initial medical market projections and is estimated that medical sales will reach approximately US\$350 million by 2022
- PA allows flower sales and, since signing the first PA deal, has added anxiety as a medical condition
- Adult-use legislation is under consideration following Governor Tom Wolf's announcement supporting recreational use in Pennsylvania

Jushi's Pennsylvania Assets

- Jushi has acquired 100% of the membership interests in four retail dispensary businesses, each having the ability to open three stores, for a total of 12 locations. This acquisition establishes Jushi as a major player in this limited license market
- Jushi has a definitive agreement in place to acquire 80% of another retail dispensary business with the ability to open an additional three locations in Southeast region
- Jushi plans to operate nine dispensaries in the greater Philadelphia region including three in Philadelphia and one in the Pittsburgh region
- Jushi has six retail dispensary businesses operational today, with nine more planned to open in the next 12 months, subject to regulatory approvals

- (1) <u>https://www.census.gov/quickfacts/fact/table/PA/PST045218</u>
- (2) <u>https://www.media.pa.gov/Pages/Health-Details.aspx?newsid=721</u>
- (3) Canaccord Genuity Global Equity Research Cannabis Industry Update (October 23, 2019)
- (4) Includes three stores in Southeast region under definitive agreement

Market Profile



(1) https://www.census.gov/quickfacts/IL

- (2) https://mjbizdaily.com/illinois-11th-state-to-legalize-adult-use-cannabis-2-billion-market-projected/
- (3) https://idfpr.com/News/2020/IDFPR%20April%20adult%20use%20cannabis%20sales.pdf

Illinois Market Overview⁽¹⁾⁽²⁾⁽³⁾

- As of July 1, 2019 Illinois has an estimated population of over 12.6 million, ranking it the sixth largest state in the country
- In June 2019, Illinois Gov. J.B. Pritzker signed a recreational marijuana legalization bill into law that became effective January 1, 2020
- The Illinois market is projected to reach \$2.5 billion in annual sales at market maturity
- In the first four months of 2020, the Illinois' Department of Financial and Professional Regulation reported that adult-use sales were over \$147 million

Jushi's Illinois Assets

- Acquired licensed business owning and operating two Illinois dispensaries one in Sauget (Adjacent to East St. Louis) and one in Normal (Bloomington-Normal metro area)
- Both dispensaries offer medical and adult-use sales (adult-use started in Sauget in March and in Normal in May)
- Each dispensary is eligible to seek approval to open one additional retail location. Jushi plans to exercise this option and operate four stores by the end of 2020

Market Profile

Prince William County: Cultivation / processing facility and retail location

(1) <u>https://wtkr.com/2018/03/11/ralph-northam-approves-groundbreaking-medical-marijuana-legislation/</u>

(2) <u>https://www.vanorml.org/2019_01_29</u>

Virginia Market Overview⁽¹⁾⁽²⁾

- Virginia has a population of over 8.5 million and is one of the country's most limited license states
- In March 2018, the governor of Virginia signed into law a bill expanding the allowable medical conditions to any diagnosed condition or disease, upon recommendation from any physician
- 62% of Virginians are in favor of ending cannabis prohibition, indicating a receptive consumer base to adult-use legislation
- In April 2020, Senate Bill 976 was enacted and allows for five additional cannabis dispensing facilities for each health service area. The bill also removed the statutory five percent cap on the concentration of THC within a cannabis oil formulation. Patients may now receive up to 10mg of THC per dose

Jushi's Virginia Assets

- Jushi acquired the majority membership interests of Dalitso, a Virginia-based pharmaceutical processor medical cannabis extracts
- The permit holder is one of five applicants to have received conditional approval for a pharmaceutical processor permit
- This license allows for cultivation, processing, dispensing and delivering throughout the state's most populous designated health service area
- Jushi anticipates adding up to five additional cannabis dispensing facilities its operations in Virginia to bring the total to six dispensaries with a capability for home deliveries

Multifaceted Branding Strategy Focused on Differentiation and Growth

Retail Brand:

- BEYOND / HELLO[™] is a leading dispensary brand focused on bringing personalized service and individualized experiences to customers beyond the first visit and first "Hello"
- Currently operate six stores in PA (opening nine more), two stores in IL (opening two more) and opening one in Santa Barbara, CA

Premium In-house Brands:

- The LabTM is the 11^{th} best selling brand in the history of legal cannabis⁽¹⁾
- Nira CBD Ultra high quality, third party tested, physician formulated hempbased CBD products
- Nira Plus First of its kind line of medical cannabis products standardized stateto-state based on clinical data
- Leveraging data analytics to drive merchandising effectiveness

Premium Third-Party Brands:

Jush

© 2020 Jushi Holdings Inc. All Rights Reserved

 Partner with "Top Tier" cannabis brands to distribute on the BEYOND / HELLO and Jushi retail, extraction and processing platform

 Source: BDS Analytics | Data includes revenues captured in Arizona, California, Colorado, Nevada, Oregon and Washington from January 2014 to July 2019

BEYOND / HELLO











Capitalization

JUSHI HOLDINGS INC. CAPITALIZATION (as of April 30, 2020)

SHARE CLASSES⁽¹⁾

Super Voting Shares (as-converted)	14,900,000
Multi Voting Shares (as-converted)	4,000,000
Subordinate Voting Shares ⁽²⁾	87,741,848
Total as-converted basic shares	106,641,848
Warrants ⁽³⁾	75,430,870
Stock Options ⁽⁴⁾	8,803,000
Fully Diluted Shares	190,875,718

- (1) Super Voting Shares are consolidated 1:100 on balance sheet (149k shares total) and have 10 votes per as-converted share. Multi Voting Shares are unconsolidated and have 10 votes per as-converted share.
- (2) Includes 24.8 million shares sold in Jushi's US\$68 million sub receipt offering and 3.3 million unvested Restricted Shares (with 1- to 3-year vesting periods). Does not include 250,000 private company shares held in escrow that may be transferred into 250,000 Subordinate Voting Shares subject to certain conditions being met.
- (3) Number of warrants shown on an as-converted basis. Weighted-average warrant strike of US\$1.57 per share, with range of US\$0.50 \$3.00.
- (4) Option strikes range from US\$1.00 \$3.00, weighted average of US\$1.89. Options vest over 3-year period.



Jushi's Future

Poised for Large Scale Growth

.Jushi

Enter New Domestic and International Markets

Expand Retail Footprint

Scale Cultivation and Manufacturing Facilities

Build Brand Awareness and Growth

Strategically Acquire Complimentary Companies and Brands

Appendix



Corporate Timeline



January 2018

Jushi was founded by Jim Cacioppo, Erich Mauff, Jon Barack and Denis Arsenault.

Acquired a cannabinoid medical research company in Buffalo. NY.

November 2018

February – March 2019 Entered a definitive agreement to acquire a cannabis retail location in

Santa Barbara – a highly affluent, limited license CA jurisdiction.

Ш

July 2019

Closed major PA acquisition, entered into MSA in NV, selected as 1 of 3 to move forward in CUP process in Culver City, CA.

December 2019 - Jan. 2020

Announced ~\$47 million debt financing. Acquired two IL medical dispensaries - one in Sauget and one in Normal. Each dispensary has the right to seek approval to open an additional location and become an adultuse dispensary. Opened 6th store in PA. Began trading on the Canadian Stock Exchange (CSE) under ticker symbol JUSH.

March 2018

Acquired 16.5% stake in New York state licensed cannabis operator.

January 2019

Launched Jushi Europe, focusing on international early stage medical market opportunities.

May – June 2019

Raised \$68.2 million in oversubscribed private placement. Listed publicly on NEO Exchange (transitioned to CSE in Dec '19). Opened CBD store in Buffalo, NY. Entered into processing MSA in Midwest.

September 2019

Opened 2 new stores in PA under BEYOND / HELLO brand (5th store), signed definitive agreement to acquire PA dispensary permittee (3 stores) and closed on acquisition in VA. Began trading on the OTCQX under ticker JUSHF and secured DTC Eligibility. Sold 16.5% stake in NY state licensed cannabis operator.



March 2020 – May 2020

Sauget, IL dispensary started adult-use sales in March. Virginia's enactment of SB 976 in April permits adding up to five additional dispensing facilities to the Virginia operations. Normal, IL dispensary started adult-use sales in May. Relaunched Beyond-Hello.com to include real-time pricing, product availability, product reservation and instore pickup.











Management Team

Experienced Talent Leading Buildout and Execution



Ryan Cook

EVP, Operations

Ryan brings extensive cannabis operations experience to his role as EVP of Operations at Jushi. Before joining Jushi, Ryan founded The Clinic[™] and served as COO the last 10 years overseeing all aspects of day-to-day operations including oversight of all retail, cultivation and manufacturing facilities. Ryan earned his degree from the University of Colorado in the School of Architecture and Planning.



Matt Leeth

EVP, Co-Head of Legal Affairs

Matt brings invaluable cannabis industry legal expertise to his role as EVP, Co-Head of Legal Affairs at Jushi. Before joining Jushi, Matt served as General Counsel at The Green Solution, one of Colorado's largest cannabis companies, and its related entities. Matt earned his BS in Civil Engineering from the University of South Florida and earned his JD from Florida State University College of Law.



Andreas "Dre" Neumann

Chief Creative Director

Dre brings over three decades of advertising, entertainment, and technology experience to his role as Chief Creative Director. Before joining Jushi, Dre served as Creative Director and Head of Content for Idean, a leading global design agency, and was instrumental in building out Idean's US footprint with key clients such as IBM, HP, Rolls Royce and Ericsson. Dre is also known for his photography and has worked with people/groups like Queens of the Stone Age, Iggy Pop, Foo Fighters, ZZ Top, and Lenny Kravitz.



Tobi Lebowitz

EVP, Co-Head of Legal Affairs

Tobi brings extensive legal and human resources expertise to Jushi. Tobi recently served as the Associate General Counsel of KLX Inc where she played a pivotal role in the sale of its aerospace segment to Boeing for \$4.25B. Tobi earned her BS from University of Florida and JD from University of Florida – Frederic G. Levin College of Law. Tobi holds a Senior Professional in Human Resources certification.



Dr. Lazlo Mechtler, MD

Medical Director, Advisor

Jushi's Medical Director, Dr. Mechtler is a world-renowned expert and a foremost leading U.S. physician in the study of therapeutic benefits of cannabinoids and related research. Dr. Mechtler is a Professor of Neurology and Oncology and has been practicing for over thirty-four years. Dr. Mechtler serves as the Medical Director of the DENT Neurologic Institute and DENT Cannabis Clinic based in Buffalo, New York.



Michael Perlman

EVP, Investor Relations & Treasurer

Michael brings vast investor relations, marketing, finance, market intelligence, and treasury experience to his role as EVP of Investor Relations & Treasurer at Jushi. Before joining Jushi, Michael served as head of Investor Relations and Treasurer at KLX Energy Services. Michael earned his BS in Finance from the University of Florida. Michael also earned his Master's in International Business from the University of Florida.



Management Team

Experienced Talent Leading Buildout and Execution



Daniel Swasbrook

EVP, President, Jushi Europe

Daniel brings vast international executive and market experience to his role as President of Jushi Europe. Daniel has a diverse range of international experience. Before joining Jushi, Daniel served as head of FRC Distribution for the Americas, Managing Director at UBS and covered global markets at both Deutsche Bank and Goldman Sachs. Daniel earned a Bachelor of Commerce, Finance & Economics from The University of Auckland and received an MBA from NYU Stern School of Business.



Nichole Upshaw

VP, Human Resources

Nichole brings invaluable experience to her role as Vice President of Human Resources. Prior to Jushi, Nichole was head of Human Resources for RaceTrac Petroleum, a convenience store chain that operates over 500 company-owned retail locations with over 9,000 employees. Nichole was a founding member of RaceTrac's Women's organization, LEAD, and has experience building affinity groups.



Trent Woloveck

EVP, Head of Origination

Trent brings singular strategic planning and strong business acquisition and development experience to his role as EVP and Head of Origination at Jushi. Trent formerly served as President of TGS National Holdings (an affiliate of The Green Solution), as well as COO at American Cannabis Company, where he worked with his clients to win state cannabis licenses. Trent earned his BS in Finance from Miami University.

Select Market Profiles



California Market Overview⁽¹⁾⁽²⁾

California is the largest cannabis market in the U.S, with ~US\$3.1 billion in sales through state-licensed channels in 2019

- By the end of 2022, estimated retail sales for both medical and adult-use cannabis are forecasted to reach US\$5.7 billion
- Market is still very much developing, as legacy operators from the decadesold black market and the younger medical gray market continue to transition into the newly regulated system

Jushi's California Assets

- Jushi has entered into a definitive agreement to acquire a Santa Barbara cannabis retail location (one of three permitted licenses in the city)
- Jushi's subsidiary has received approval to move forward in permitting an adult-use retail and delivery location in Culver City (one of three permitted licenses in the city)

- BDS Analytics
- Canaccord Genuity Global Equity Research Cannabis Industry Update (October 23, 2019) (2)

Overview⁽¹⁾⁽²⁾ residents

Nevada Market

- Developed medical and adult-use markets
- Projected cannabis sales are expected to reach ~US\$950 million by 2022

Buffalo: CBD retai location

- The City of Las Vegas is one of the most visited cities in the U.S with ~60 million visitors annually and 3 million

New York Market Overview

- New York State is expected to become one of the largest CBD markets in the US based on rapid consumer adoption and New York's affluent consumer base and population size
- Since the 2018 Farm Bill was signed into law more than a year ago, New Jushi office location York has made a meaningful effort to support the State's hemp industry by incorporating product testing and other quality-based standards into new legislation

Jushi's Nevada Assets

- Jushi's subsidiary, Production Excellence, entered into management services agreement with Franklin Bioscience Nevada
- Further, Production Excellence is under definitive agreement to acquire 100% equity of Franklin Bioscience Nevada, subject to regulatory approvals
- Jushi has also completed the purchase of the real estate associated with Franklin Bioscience Nevada's facility in North Las Vegas, Nevada
- Franklin Bioscience holds medical and adult use cannabis cultivation. processing, distribution and hemp handler licenses
- https://www.lvcva.com/stats-and-facts/visitor-statistics/

North Las Vegas:

Cultivation / processing

facility

Canaccord Genuity Global Equity Research – Cannabis Industry Update (October 23, 2019)

Jushi's New York Assets

New York City:

- Sound Wellness, a Jushi subsidiary, was awarded an Industrial Hemp CBD Processor License by the New York State Department of Agriculture and Markets
- CBD retail location operational within Dent Neurological Institute near Buffalo, NY
- Sold 16.5% stake in parent company of New York state licensed cannabis operator. Sold for highly favorable ROI: the cash and securities received in sale has a total value of approximately \$15-20 million depending on contingency payouts

© 2020 Jushi Holdings Inc. All Rights Reserved

Thank you

Contact Information

Michael Perlman EVP, Investor Relations & Treasurer

1800 NW Corporate Blvd, Suite 200 Boca Raton, FL 33431

561.453.1308 mperlman@jushico.com investors@jushico.com www.jushico.com



Risk Factors

An investment in the securities described herein is speculative and involves a number of risks that should be considered by a prospective investor. Prospective investors should carefully consider the risk factors described under "Risk Factors" in the Appendix at the end of this presentation and those contained in the Company's Management Discussion & Analysis dated May 7, 2020 as filed on SEDAR, before investing in the Company and purchasing the securities described herein.

UNCERTAINTY CAUSED BY NEW AND CHANGING REGULATORY FRAMEWORK

There is substantial uncertainty regarding federal, state and local regulation of both cannabis and hemp described more fully in the Risk Founders contained in the CSE Form 2A Listing Statement. Federal, state and local governments are developing new regulations and amending current regulations, of which some are subject to varying interpretations, under which the Company is and/or will operate. Accordingly, there is uncertainty as to the restrictions placed on the Company and the industry. If these uncertainties continue, they may have an adverse effect upon the introduction of the Company's products in different markets.

BANKING LIMITATIONS NEGATIVELY IMPACT BUSINESS IN THE CANNABIS INDUSTRY

The terms cannabis and marijuana are terms generally used to describe the products and derivatives of the cannabis plant. The use of those terms varies by federal, state and local regulators and in federal, state and local laws, rules, regulations and ordinances and can create confusion. The possession and use of cannabis for any purposes is illegal under federal law. Therefore, there is a strong argument that banks cannot, and they typically do not, accept for deposit funds from the drug trade and therefore cannot do business with businesses engaged in the production, sale or distribution of cannabis, as well as businesses that provide products and services to these businesses, despite the fact that the activities in which these businesses engage may be legal under applicable state law. While the Company currently has a banking relationship, there can be no assurances that the Company will be able to maintain this relationship. On February 14, 2014, FinCEN released guidance to banks clarifying BSA expectations for financial institutions seeking to provide services to cannabis-related businesses." Even with the FinCEN guidance, however, there can be no guaranty that banks will decide to do business with businesses in the cannabis industry, or that, in the absence of actual legislation, state and federal banking regulators will not strictly enforce current prohibitions on banks handling funds generated from an activity that is illegal under federal law. The inability of businesses to prosper and expand, which could have a significant and negative impact on such businesses and their operations and financial condition.

SCIENTIFIC RESEARCH RELATED TO THE BENEFITS OF CANNABIS REMAINS IN EARLY STAGES IS SUBJECT TO A NUMBER OF IMPORTANT ASSUMPTIONS, AND MAY PROVE TO BE INACCURATE

Research in Canada, the United States and internationally regarding the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids remains in early stages. To the Company's knowledge, there have been relatively few double-blind placebo-controlled clinical trials on the benefits of cannabis or isolated cannabinoids. Any statements made in this Presentation concerning cannabis's or cannabinoids' potential medical benefits are based on published articles and reports. As a result, any statements made in this Presentation are subject to the experimental parameters, qualifications, assumptions and limitations in the studies that have been completed.

Although the Company believes that the articles and reports, and details of research studies and clinical trials that are publicly available reasonably support its beliefs regarding the medical benefits, viability, safety, efficacy and dosing of cannabis, future research and clinical trials may prove such statements to be incorrect or could raise concerns regarding and perceptions relating to cannabis. Given these risks, uncertainties and assumptions, prospective purchasers under investors should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated in this Presentation or reach negative conclusions regarding the viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to medical cannabis, which could materially impact the Company.

TAXATION

Prospective investors should be aware that the purchase of securities of the Company or any entity related thereto may have tax consequences both in Canada and the United States. Each prospective investor is strongly encouraged to consult its own tax advisor concerning any purchase of securities of the Company or any entity related thereto and the holding and disposition of any such securities. This presentation does not address the tax consequences of the purchase, ownership or disposition of any such securities.